KIT D820Y

CI-VAR-00000566Explore in graph →NP_000213.1:p.Asp820TyrNM_000222.2:c.2458G>TClinVar 375928 CIViC 986 rs1057519710

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor1
KIT D820Y	Regorafenib Anhydrous	Predictive	C	Supports Sensitivity Response	2	accepted	EID4589 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
Melanoma3
KIT D820Y	(prognostic)	Prognostic	C	Supports N/A	2	submitted	EID2887 261 Australian patients with melanoma were screened for mutations in KIT exons 11,13 and 17. 5 KIT mutations were found, including in 2 of the 4 total acral melanomas assessed. 1 subject with acral me… (full text at CIViC) PMID 20088873 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375928	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Gastrointestinal stromal tumor; Hereditary cancer-predisposing syndrome	germline	3	Feb 04, 2025	clinvar